MedTrace Logo

Lung Cancer Information Study (LCIS-R01)

NCT01924416 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2018-02-19

No results posted yet for this study

Summary

The primary specific aim is to test the hypothesis that use of a decision aid to enhance informed, shared decision making coupled with quality of life assessment in patients with advanced lung cancer receiving first-, second-, or third-line therapy will lead to a reduction in two major contributors of cost (number of chemotherapy cycles; number of advanced imaging studies) compared with the control arm.

Conditions

  • Non-Small-Cell Lung Cancer

Interventions

BEHAVIORAL

Enhanced Care (intervention group and comparison group)

Decision aid coupled with immediate QL-PRO results

BEHAVIORAL

Usual care (routine chemotherapy cycles and imaging studies)

Usual care does not receive intervention

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Virginia

    lead OTHER

Principal Investigators

  • Patricia J Hollen, PhD · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01924416 on ClinicalTrials.gov